Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (AFMD) has been a Nasdaq-listed, clinical-stage immuno-oncology company focused on innate cell engagers (ICE®) generated on its proprietary ROCK® platform. Company news has highlighted how these ICE® molecules are being developed to recognize and kill a range of hematologic and solid tumors by engaging innate immune cells.
News coverage for AFMD includes detailed clinical updates on key ICE® programs such as AFM24, AFM28 and acimtamig (AFM13). Releases describe AFM24 as a tetravalent, bispecific ICE® targeting CD16A and EGFR, with data in advanced or metastatic non-small cell lung cancer, including combinations with atezolizumab. For AFM28, Affimed has reported early Phase 1 results in relapsed/refractory acute myeloid leukemia, including composite complete remission rates and safety findings. Additional news has covered acimtamig in combination with AlloNK® (AB-101) in classical Hodgkin lymphoma, with abstracts accepted for major oncology meetings.
Another important category of AFMD news relates to corporate and listing developments. In May 2025, Affimed announced that it had filed for insolvency proceedings in Mannheim, Germany, citing overindebtedness and liquidity concerns. Shortly thereafter, the company disclosed that Nasdaq staff would suspend trading of its common shares and proceed with a delisting process, culminating in a Form 25 filing to remove its common stock from Nasdaq listing and registration.
On this news page, readers can review historical press releases on AFMD’s clinical trial data, conference presentations, investor webcasts, and regulatory and listing updates. For those tracking the company’s ICE® pipeline and its insolvency and delisting process, this archive offers a centralized view of how Affimed’s scientific, clinical, and corporate story has evolved over time.
Affimed N.V. (Nasdaq: AFMD) reported strong financial results for Q1 2021, with total revenue reaching €11.7 million, up from €5.1 million year-over-year. The company's cash and cash equivalents stood at €240.7 million, ensuring operations through the second half of 2023. Key clinical updates include positive interim results for AFM13 in PTCL and a 100% response rate in a combination therapy trial with NK cells. Comprehensive plans for upcoming trials of AFM24 and AFM28 show promise for further development. A conference call is scheduled for July 1, 2021, to discuss these results.
Affimed N.V. (Nasdaq: AFMD) will release its first-quarter 2021 financial results on July 1, 2021. A conference call will occur at 8:30 a.m. EDT to discuss these results and recent corporate developments. Stakeholders can access the call via phone or live audio webcast. Additionally, the company's innovative ROCK® platform aims to enhance cancer treatment through the innate immune system, positioning Affimed as a leader in immuno-oncology with a clinical-stage ICE®. Further information is available on their website.
Affimed N.V. (Nasdaq: AFMD) announced the appointment of Ms. Uta Kemmerich-Keil to its Supervisory Board, effective immediately from June 15, 2021. Approved during the Annual General Meeting, her extensive experience in the life sciences sector, particularly in leading global pharmaceutical companies, positions her to provide significant guidance in advancing Affimed's immuno-oncology pipeline. Kemmerich-Keil previously held senior roles at companies like P&G and Merck KGaA, bringing valuable financial and strategic expertise to Affimed’s growth strategy.
Affimed N.V. (Nasdaq: AFMD) announced that its CEO, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:30 a.m. Eastern Time.
A live webcast can be accessed on Affimed’s website, with an archived replay available for 30 days post-event.
Affimed is focused on immuno-oncology and utilizes its proprietary ROCK® platform to harness the innate immune system in cancer treatment, developing innovative therapies to target various tumors.
Affimed N.V. (Nasdaq: AFMD) announced that its 2021 Annual General Meeting (AGM) will take place on June 15, 2021, at 17:30 PM CET (11:30 AM EDT). In light of the ongoing COVID-19 pandemic, the meeting will be held virtually to ensure the safety of shareholders. Interested parties can access the meeting via the designated link. The notice and agenda for the meeting are accessible on the company’s website and the SEC’s website.
Affimed N.V. (Nasdaq: AFMD) announced promising preclinical results for AFM13, an innate cell engager (ICE®) targeting CD30-positive tumors. The data showed that AFM13 enhanced the efficacy of natural killer (NK) cells in recognizing and killing tumor cells both in vitro and in vivo. This supports the ongoing Phase I clinical trial of AFM13 pre-complexed with NK cells. Notably, early Phase 1 data revealed a 100% objective response rate among heavily pretreated patients, with no severe side effects reported. These findings highlight AFM13's potential as an innovative cancer treatment.
Affimed N.V. (Nasdaq: AFMD) reported positive interim results for its AFM13 monotherapy study in PTCL, achieving a 100% objective response rate in four evaluable patients, including two complete responses. The company also provided updates on clinical trials for AFM24, including a cleared IND application for its combination with NKGen's SNK-01. Financially, Affimed showed a pro forma cash position of approximately €244.5 million as of December 31, 2020, which supports operations through mid-2023. Total revenue rose to €28.4 million in 2020, driven largely by collaborations with Genentech and Roivant.
Affimed N.V. (Nasdaq: AFMD) has announced promising pre-clinical data for its Innate Cell Engager (ICE®) AFM24, demonstrating significant tumor cell killing capabilities independent of KRAS mutations. Presented at the AACR Virtual Annual Meeting, AFM24 shows potential in combination with adoptively transferred NK cells, leading to dose-dependent tumor regression. This innovative mechanism may change the treatment landscape for EGFR-expressing solid tumors. The company continues to evaluate AFM24 for patients with advanced malignancies, supported by regulatory approvals for ongoing clinical trials.
Affimed N.V. (Nasdaq: AFMD) announced promising initial results from a Phase 1 trial at MD Anderson, showcasing a 100% objective response rate in four patients with recurrent/refractory CD30-positive lymphomas. Among these, two achieved complete responses and two had partial responses. Importantly, there were no signs of cytokine release syndrome or neurotoxicity. The trial, which utilizes cord blood-derived NK cells pre-complexed with Affimed's AFM13, is continuing to enroll patients for further cohorts. A conference call is scheduled for April 14 to discuss these findings.
Affimed N.V. (Nasdaq: AFMD) will report its 2020 financial results and corporate updates on April 15, 2021, with a conference call at 8:30 a.m. EDT. Investors can join via phone or webcast, accessing the call with specific dial-in numbers and a conference ID.
Affimed is focused on immuno-oncology, leveraging its proprietary ROCK® platform to develop therapies aimed at treating various tumors. The company aims to empower patients' innate immunity to combat cancer effectively.